A Protocol for Active Surveillance of Acute Myocardial Infarction in Association with the use of a New Antidiabetic Pharmaceutical Agent

Project Title A Protocol for Active Surveillance of Acute Myocardial Infarction in Association with the use of a New Antidiabetic Pharmaceutical Agent
Date
Wednesday, January 18, 2012
Location

Pharmacoepidemiology and Drug Safety, Volume 21, Issue Supplement S1, January 2012, Pages 282-290, DOI: 10.1002/pds.2337

Description

This article describes a protocol for active surveillance of acute myocardial infarction (AMI) in users of a recently approved oral antidiabetic medication, saxagliptin, along with several comparators, and provides the rationale for decisions made in drafting the protocol.

Medical Product
oral antidiabetic medication
saxagliptin
Health Outcome
acute myocardial infarction (AMI)
Population / Cohort
diabetics
Corresponding Author

Bruce Fireman, Division of Research, Kaiser Permanente, 2000 Broadway, Oakland, CA 94612, USA. E-mail: bruce.fireman@kp.org

Authors

Bruce Fireman MA; Sengwee Toh ScD; Melissa G. Butler PharmD, PhD, MPH; Alan S. Go MD; Hylton V. Joffe MD, MMSc; David J. Graham MD, MPH; Jennifer C. Nelson PhD; Gregory W. Daniel PhD, MPH, RPH; Joe V. Selby MD, MPH

Related Assessments
Anti-Diabetes Drugs and Acute Myocardial Infarction, Hospitalized Heart Failure
Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study
Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study
Sentinel Initiative Public Workshop - Ninth Annual
Publication Type
Publication
Scroll to Top